Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Leases (2023 - 2025)

Historic Operating Leases for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Q3 2025 value amounting to $8.4 million.

  • Centessa Pharmaceuticals' Operating Leases fell 639.69% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 639.69%. This contributed to the annual value of $8.3 million for FY2024, which is 677.32% down from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Operating Leases is $8.4 million, which was down 639.69% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Operating Leases registered a high of $9.7 million during Q1 2023, and its lowest value of $8.3 million during Q4 2024.
  • In the last 3 years, Centessa Pharmaceuticals' Operating Leases had a median value of $9.0 million in 2024 and averaged $9.0 million.
  • Examining YoY changes over the last 5 years, Centessa Pharmaceuticals' Operating Leases showed a top increase of 423.23% in 2024 and a maximum decrease of 677.32% in 2024.
  • Quarter analysis of 3 years shows Centessa Pharmaceuticals' Operating Leases stood at $8.9 million in 2023, then fell by 6.77% to $8.3 million in 2024, then grew by 1.89% to $8.4 million in 2025.
  • Its last three reported values are $8.4 million in Q3 2025, $8.6 million for Q2 2025, and $8.7 million during Q1 2025.